Simple Summary Similarly to other solid malignancies, there is a growing interest in testing
immune checkpoint inhibitors (ICIs) for thymic epithelial tumors (TETs). However, the thymus …

Simple Summary Immunotherapy has a rapidly expanding role for the treatment of several
cancers due to durable clinical activity and favorable tolerability. However, the unique …

Thymic epithelial tumors (TETs) are a rare group of malignancies arising from the thymus.
Surgery remains the foundation of treatment for patients with early‐stage disease. Limited …

Thymomas and thymic carcinomas (TCs)(also known as Thymic Epithelial Tumors or TETs)
are rare cancers and the most frequent masses of the anterior mediastinum. These tumors …

Thymic epithelial tumors (TETs) are a group of rare thoracic malignancies, including thymic
carcinomas (TC) and thymomas (Tm). Autoimmune paraneoplastic diseases are often …

Background Thymic epithelial tumors (TETs) are rare malignant neoplasms originating from
thymic epithelial cells. The current treatment for localized TETs is surgical removal …

Simple Summary Immune checkpoint inhibitors have revolutionized cancer therapy and
improved clinical outcomes. Immunotherapy is now increasingly combined with …

Thymic epithelial tumors (TETs), including thymomas and thymic carcinomas, are rare
malignancies arising from the thymus gland. The optimal management requires a …

Simple Summary Treatment options for advanced thymic malignancies are limited. Immune
checkpoint inhibitors are effective against advanced thymic epithelial tumors, but the …

Thymic epithelial tumors (TETs) are rare malignant neoplasms arising in the thymus gland.
Nevertheless, TETs, including thymomas (TMs), thymic carcinomas (TCs), and thymic …